These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 37471178)

  • 1. Epcoritamab-bysp.
    Am J Health Syst Pharm; 2023 Sep; 80(19):1289-1292. PubMed ID: 37471178
    [No Abstract]   [Full Text] [Related]  

  • 2. Epcoritamab: First Approval.
    Frampton JE
    Drugs; 2023 Sep; 83(14):1331-1340. PubMed ID: 37597091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epcoritamab-bysp (Epkinly) - A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma.
    Riaz R; Khan A; Siddiqui T
    Rare Tumors; 2023; 15():20363613231193566. PubMed ID: 37534337
    [No Abstract]   [Full Text] [Related]  

  • 4. Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting.
    Mhibik M; Gaglione EM; Eik D; Herrick J; Le J; Ahn IE; Chiu C; Wielgos-Bonvallet M; Hiemstra IH; Breij ECW; Chen J; Reilly EB; Epling-Burnette PK; Szafer-Glusman E; Sun C; Wiestner A
    Blood Adv; 2023 Aug; 7(15):4089-4101. PubMed ID: 37219524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.
    van der Horst HJ; de Jonge AV; Hiemstra IH; Gelderloos AT; Berry DRAI; Hijmering NJ; van Essen HF; de Jong D; Chamuleau MED; Zweegman S; Breij ECW; Roemer MGM; Mutis T
    Blood Cancer J; 2021 Feb; 11(2):38. PubMed ID: 33602901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.
    Hutchings M; Mous R; Clausen MR; Johnson P; Linton KM; Chamuleau MED; Lewis DJ; Sureda Balari A; Cunningham D; Oliveri RS; Elliott B; DeMarco D; Azaryan A; Chiu C; Li T; Chen KM; Ahmadi T; Lugtenburg PJ
    Lancet; 2021 Sep; 398(10306):1157-1169. PubMed ID: 34508654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
    Thieblemont C; Phillips T; Ghesquieres H; Cheah CY; Clausen MR; Cunningham D; Do YR; Feldman T; Gasiorowski R; Jurczak W; Kim TM; Lewis DJ; van der Poel M; Poon ML; Cota Stirner M; Kilavuz N; Chiu C; Chen M; Sacchi M; Elliott B; Ahmadi T; Hutchings M; Lugtenburg PJ
    J Clin Oncol; 2023 Apr; 41(12):2238-2247. PubMed ID: 36548927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semimechanistic Physiologically-Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B-Cell Lymphomas.
    Li T; Hiemstra IH; Chiu C; Oliveri RS; Elliott B; DeMarco D; Salcedo T; Egerod FL; Sasser K; Ahmadi T; Gupta M
    Clin Pharmacol Ther; 2022 Nov; 112(5):1108-1119. PubMed ID: 35996883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epcoritamab (Epkinly) for diffuse large B-cell lymphoma (DLBCL).
    Med Lett Drugs Ther; 2023 Jun; 65(1678):e103-e104. PubMed ID: 37339097
    [No Abstract]   [Full Text] [Related]  

  • 10. The Bispecific Antibody Epcoritamab Produces Responses in Lymphoma.
    Cancer Discov; 2021 Nov; 11(11):2671. PubMed ID: 34535461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epcoritamab is active in large B cell lymphomas.
    Romero D
    Nat Rev Clin Oncol; 2023 Mar; 20(3):138. PubMed ID: 36646813
    [No Abstract]   [Full Text] [Related]  

  • 12. Glofitamab (Columvi) for diffuse large B-cell lymphoma.
    Med Lett Drugs Ther; 2023 Aug; 65(1682):e129-e130. PubMed ID: 37516899
    [No Abstract]   [Full Text] [Related]  

  • 13. Update on bi-specific monoclonal antibodies for blood cancers.
    Shouse G
    Curr Opin Oncol; 2023 Sep; 35(5):441-445. PubMed ID: 37551951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting.
    Liu X; Zhao J; Guo X; Song Y
    J Hematol Oncol; 2023 Aug; 16(1):90. PubMed ID: 37537626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular and behavioural effects of centrally administered tachykinins in the rat: characterization of receptors with selective antagonists.
    Picard P; Regoli D; Couture R
    Br J Pharmacol; 1994 May; 112(1):240-9. PubMed ID: 7518304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The shifting therapeutic paradigm for relapsed/refractory mantle cell lymphoma.
    Arun Kumar S; Gao J; Patel SA
    Leuk Res; 2023 Nov; 134():107385. PubMed ID: 37672954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas.
    Gao J; Dahiya S; Patel SA
    Br J Haematol; 2023 Oct; 203(2):161-168. PubMed ID: 37488074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
    Bock AM; Nowakowski GS; Wang Y
    Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders.
    Mihályová J; Hradská K; Jelínek T; Motais B; Celichowski P; Hájek R
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in indolent Non-Hodgkin's Lymphoma.
    Amhaz G; Bazarbachi A; El-Cheikh J
    Leuk Res Rep; 2022; 17():100325. PubMed ID: 35663281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.